Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;174(3):382-96.
doi: 10.1111/bjh.14061. Epub 2016 Apr 7.

Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12

Samer A Srour  1   2 , Susan S Devesa  3 , Lindsay M Morton  3 , David P Check  3 , Rochelle E Curtis  3 , Martha S Linet  3 , Graça M Dores  1   3
Affiliations

Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12

Samer A Srour et al. Br J Haematol. 2016 Aug.

Erratum in

  • Editor's note.
    [No authors listed] [No authors listed] Br J Haematol. 2017 Apr;177(2):331. doi: 10.1111/bjh.14674. Br J Haematol. 2017. PMID: 28387461 No abstract available.

Abstract

Descriptive epidemiological information on myeloproliferative neoplasms (MPNs) and myelodysplastic (MDS)/MPNs is largely derived from single institution and European population-based studies. Data obtained following adoption of the World Health Organization classification of haematopoietic neoplasms and JAK2 V617F mutation testing are sparse. Using population-based data, we comprehensively assessed subtype-specific MPN and MDS/MPN incidence rates (IRs), IR ratios (IRRs) and relative survival (RS) in the United States (2001-12). IRs were highest for polycythaemia vera (PV) (IR = 10·9) and essential thrombocythaemia (ET) (IR = 9·6). Except for ET and mastocytosis, overall IRs were significantly higher among males (IRRs = 1·4-2·3). All evaluable MPNs were associated with lower IRs among Hispanic whites than non-Hispanic whites (NHWs), with the exception of BCR-ABL1-positive chronic myeloid leukaemia (CML), chronic eosinophilic leukaemia (CEL) and juvenile myelomonocytic leukaemia. Except for CEL, Asians/Pacific Islanders had significantly lower MPN IRs than NHWs. ET, MPN-unclassifiable and CEL IRs were 18%, 19% and 60% higher, respectively, among blacks than NHWs. Five-year RS was more favourable for younger (<60 years) than older individuals and for women compared with men, except for PV at older ages. RS was highest (>90%) for younger PV and ET patients and lowest (<20%) for older chronic myelomonocytic leukaemia and atypical BCR-ABL1-negative CML patients. Varying MPN and MDS/MPN incidence patterns by subtype support distinct aetiologies and/or susceptible populations. Decreased survival rates as compared to that expected in the general population were associated with every MPN subtype, highlighting the need for new treatments, particularly among older individuals.

Keywords: epidemiology; incidence; myeloproliferative neoplasm; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Age-specific incidence rates of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms according to sex, SEER-18, 2001-2012
Per SEER Program convention, IRs based on fewer than 16 cases were omitted from the figure (Howlader, et al 2015).
Figure 2
Figure 2. Age-adjusted incidence rates of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms, according to year of SEER submission file, SEER-17, 2001-2012
The six 2-year calendar periods reflecting year of diagnosis include 2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010, and 2011–2012.
Figure 3
Figure 3. Relative survival of patients with myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms according to sex and age at diagnosis, SEER-18, 2001-2012
Individuals were diagnosed 2001-2011 and followed through 2012. Survival is presented by sex and age (<60 years vs. ≥60 years) at diagnosis. Survival rates based on fewer than 25 cases (total) were omitted from the figure. The total number of cases among each sex/age group is indicated within the legend.
See this image and copyright information in PMC

References

    1. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andreasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2010;86:148–155. - PubMed
    1. Alvarez-Larran A, Ancochea A, Garcia M, Climent F, Garcia-Pallarols F, Angona A, Senin A, Barranco C, Martinez-Aviles L, Serrano S, Bellosillo B, Besses C. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol. 2014;166:911–919. - PubMed
    1. Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012;87:175–182. - PubMed
    1. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Mullauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–3184. - PubMed
    1. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) Blood. 2012;120:5128–5133. quiz 5252. - PubMed